Tesamorelin vs CJC-1295 Naming Conventions Explained

Tesamorelin vs CJC-1295 naming conventions cause confusion because both terms sit under the same broad category — growth-hormone-releasing hormone (GHRH) analogs — while naming two structurally distinct sequences that are not interchangeable on a listing or a specification sheet. Tesamorelin is a specific, single, FDA-recognized GHRH analog with one defined sequence. CJC-1295 is a name that itself splits into two different naming conventions depending on whether a listing means the version with a stability-extending modification (often written as CJC-1295 with DAC) or the shorter-acting version without it (sometimes written as CJC-1295 without DAC, or conflated with a separate peptide called Mod GRF 1-29). Reading a listing correctly means recognizing which naming layer is in play before comparing anything else.

What “Tesamorelin” Names as a Single Term

Tesamorelin’s naming is comparatively simple: the word refers to one defined amino acid sequence, a synthetic analog of GHRH engineered for a stabilized structure. Reference listings and certificates of analysis that use “tesamorelin” are naming a single, consistent compound. Where naming variation appears for tesamorelin, it is usually limited to whether the salt form is specified — for example “tesamorelin acetate” versus “tesamorelin” alone — rather than any ambiguity about which peptide sequence is meant. That single-sequence clarity is one of the more useful reference points when comparing it against CJC-1295 naming, which does not carry the same simplicity.

Why “CJC-1295” Splits Into Two Naming Conventions

CJC-1295 naming conventions are more layered because the name has historically been applied to two related but distinct constructs. The original CJC-1295 refers to a GHRH analog modified with a drug affinity complex (DAC), a chemical addition intended to extend the molecule’s circulating stability compared to unmodified GHRH analogs. Over time, the bare name “CJC-1295” has also been used loosely by some listings to refer to a shorter fragment that lacks the DAC modification — a sequence more accurately called CJC-1295 without DAC, which is chemically closer to Mod GRF 1-29 than to the DAC-modified original. This means two vials both labeled “CJC-1295” from different sources can, in principle, refer to different molecules unless the listing specifies the DAC status explicitly.

Naming Term	What It Specifies	Naming Ambiguity Risk
Tesamorelin	One defined GHRH analog sequence	Low — variation limited to salt-form labeling
CJC-1295 (with DAC)	GHRH analog plus stability-extending modification	Moderate — DAC status must be stated explicitly
CJC-1295 (without DAC)	Shorter GHRH-analog fragment, no DAC	High — frequently conflated with Mod GRF 1-29

Reading a Listing’s Full Name, Not Just the Shorthand

Because of this split, the more reliable way to interpret tesamorelin vs CJC-1295 naming conventions on any given page is to read the full compound name rather than the shorthand alone. A specification sheet that states “CJC-1295 with DAC” or “CJC-1295, no DAC” is being precise about which construct it means. A listing that simply says “CJC-1295” without qualification is using the term more loosely, and a reader comparing it against a tesamorelin listing should not assume the two naming conventions carry equivalent specificity. Tesamorelin’s naming does not require this same qualification step, since there is no parallel DAC/no-DAC split for that compound.

How This Naming Difference Affects Reconstitution Math

The naming distinction itself does not change how concentration is calculated — that math is the same formula regardless of which GHRH analog is in the vial — but it does matter which labeled mg figure is entered into the formula, since tesamorelin and CJC-1295 vials are typically sold in different standard strengths. Concentration is calculated as vial mg divided by mL of bacteriostatic water added. Take a vial labeled 2 mg tesamorelin reconstituted with 2 mL of bacteriostatic water:

concentration = 2 mg ÷ 2 mL = 1 mg/mL

Converting to micrograms: 1 mg/mL × 1000 mcg/mg = 1000 mcg/mL. On a U-100 insulin syringe, 1 mL equals 100 units, so each unit corresponds to 0.01 mL, meaning one unit equals 0.01 mL × 1000 mcg/mL = 10 mcg. Checking this a second way: the full 2 mL draws as 200 unit-equivalents (2 mL ÷ 0.01 mL per unit), and 2000 mcg ÷ 200 units = 10 mcg per unit, matching the first calculation. This worked example applies the same underlying formula that would be used for a CJC-1295 vial at its own labeled strength; the naming convention on the label identifies which compound is present, not how the concentration formula itself is applied.

Why Precise Naming Matters for Comparing Listings

A reader trying to compare tesamorelin against CJC-1295 across different catalogue pages benefits from checking each listing’s certificate of analysis rather than relying on the product title alone, since “CJC-1295” without qualification carries more room for ambiguity than “tesamorelin” does. Reference catalogues that document both compounds, including listings maintained by HEEZ Research, typically state the full compound name — including DAC status for CJC-1295 — alongside the peptide mg content, which is the detail that resolves naming ambiguity more reliably than the shorthand term used in a page’s headline. Readers researching vial strengths and reconstitution details across this cluster can also cross-reference figures against peer tesamorelin listing catalogs, which tracks how naming and strength variations show up across listings for this specific compound.

Naming Precision as the Practical Takeaway

The core difference in tesamorelin vs CJC-1295 naming conventions is that tesamorelin names one defined sequence with minimal ambiguity, while CJC-1295 functions as an umbrella term that splits into DAC and no-DAC variants requiring explicit qualification to interpret correctly. Treating “CJC-1295” as self-explanatory risks conflating two chemically distinct constructs, whereas “tesamorelin” carries that specificity by default. Checking a listing’s full stated name, rather than its shorthand, remains the most reliable way to confirm which molecule a given vial or specification sheet is actually describing.

Summary

Tesamorelin refers to a single, consistently named GHRH analog, while CJC-1295 naming conventions split between a DAC-modified version and a shorter fragment often labeled without qualification. This asymmetry means listings using “CJC-1295” require a closer read of the full compound name to confirm which construct is meant, while tesamorelin’s naming carries that clarity without additional qualification. The underlying reconstitution math is identical for both once the correct labeled mg figure is known, but confirming which compound and which naming variant a listing describes is the necessary first step before that math is applied.